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Abstract Investments in community-based HIV preven-
tion programs in Ontario over the past two and a half
decades are assumed to have had an impact on the HIV
epidemic, but they have never been systematically evalu-
ated. To help close this knowledge gap, we conducted a
macro-level evaluation of investment in Ontario HIV pre-
vention programs from the payer perspective. Our results
showed that, from 1987 to 2011, province-wide commu-
nity-based programs helped to avert a total of 16,672 HIV
infections, saving Ontario’s health care system approxi-
mately $6.5 billion Canadian dollars (range 4.8–7.5B). We
also showed that these community-based HIV programs
were cost-saving: from 2005 to 2011, every dollar invested
in these programs saved about $5. This study is an
important first step in understanding the impact of invest-
ing in community-based HIV prevention programs in
Ontario and recognizing the impact that these programs
have had in reducing HIV infections and health care costs.
Resumen En Ontario, inversiones de programas para
prevencio´n de VIH con base comunitaria, se han llevado
acabo, durante las u´ltimas dos de´cadas. Estos esfuerzos se
han presumido como efectivos, aunque sin por el momento,
se hayan realizado evaluaciones sistema´ticas. Para ayudar a
cerrar la ausencia de conocimiento, se condujo una eva-
luacio´n a nivel macro, sobre la inversio´n de programas de
prevencio´n de VIH en Ontario, desde la perspectiva de los
contribuidores de impuestos. Los resultados muestran que:
desde 1987 hasta el 2011, los programas comunitarios de
prevencio´n provinciales ayudaron a prevenir un total de 16,
672 (nuevas) infecciones de VIH, ahorra´ndole al sistema de
salud de Ontario aproximadamente $6.5 billones de do´lares
(rango: $4.8 B-$7.5 B). Tambie´n mostramos que los pro-
gramas comunitarios de prevencio´n, desde el 2005 al 2011,
ahorraron de cada do´lar invertido, $5 do´lares (CAD). Este
estudio es un paso importante para el entendimiento del
impacto de la inversio´n en programas con base comunitaria,
y reconoce el impacto que estos programas han tenido en la
reduccio´n de infecciones de VIH y el costo en el cuidado de
la salud, en Ontario.
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Introduction
The economic burden of HIV infection is substantial. In the
United States, on average, the life-time cost per case is
estimated as ranging from $253,000 to $402,000 (USD)
[1]. Over the past two and a half decades, community-
based programs and behavioural prevention strategies have
played key roles in HIV and sexually transmitted infection
prevention in Canada, the United States, Australia, the
United Kingdom and elsewhere. A significant body of
evidence has demonstrated that community-based and
behavioural interventions are effective in: reducing risky
sexual behaviour and the incidence of sexually transmitted
infections in high-risk populations [2–7]; increasing con-
dom use [8–10]; increasing knowledge of HIV transmis-
sion and prevention [7]; improving adherence to
antiretroviral therapy [11]; and improving retention to care
and treatment [6, 12]. Since the beginning of the HIV
epidemic, Ontario’s HIV prevention strategies have relied
heavily on province-wide, community-based HIV organi-
zations to deliver prevention programs, educate popula-
tions and communities at-risk, and develop meaningful
relationships with the community [13, 14]. In its prevention
strategies, the province has strategically taken into account
the impact of stigma, culture and human rights, as well as
the social, behavioural and structural factors that affect
HIV risk [13, 14].
Though many community-based behavioural HIV pre-
vention programs have been shown to be successful, their
outcomes often rely on self-reported behaviour change.
The link between investments in these programs and the
actual reduction of HIV infections is not well understood.
However, understanding the link is vital for health planners
and policy decision makers trying to determine whether
allocating scarce resources to these programs is good value
for money.
The major difficulty in understanding the impact of
investment is the long causal pathway that runs between
investments made and actual reductions in HIV infections.
The impact of investment may take many years and, along
the way, there are many confounding factors that might
influence final outcome(s). Despite these difficulties,
researchers at the U.S. Centers for Disease Control and
Prevention (CDC) have created methodologies and models
to evaluate the economic impact of HIV prevention pro-
grams and to provide support in recent years for funding
resource allocation in the U.S. [15–21]. A correlation
analysis showed that U.S. investments in HIV prevention
appear to be correlated with the reduction of HIV incidence
from 1985 to 2006 [22]. Another U.S. analysis found that
investments in HIV prevention programs between 1991 and
2006 helped to avert 361,878 new HIV cases and saved the
U.S. health care system $130 billion [17]. A model-based
evaluation study has shown that most non-biomedical,
community-based and behavioural interventions are cost
saving [23]. An optimal portfolio of cost-saving interven-
tions could reduce new HIV cases by 34 % and save $5
billion (USD) over the next 20 years [23]. Substantially
scaling up cost-effective HIV prevention programs in the
future may help avert new HIV cases and reduce costs in
the U.S. and other countries [18–21].
To our knowledge, no similar evaluation analysis has
been done for province-wide, community-based programs
for HIV prevention in Ontario; there has also been no
analysis of the level of investment required to have an
impact. We took a first step to evaluate community-based
HIV prevention programs and strategies at the macro level
in the social and political context of Ontario, Canada. We
did this by: retrospectively quantifying the historical
impacts of community-based programs for HIV prevention
in Ontario from 1987 to 2011; estimating the economic
impacts of these programs from the payer perspective; and
evaluating the financial return on investment of Ontario’s
community-based programs for HIV prevention.
Materials and Methods
To evaluate the historical and economic impacts of
Ontario’s community-based programs, we applied well-
established methods used to evaluate the publicly-funded
U.S. investments in HIV prevention strategies [15–21].
This study was based on aggregate data, so did not require
institutional ethical approval. All data used in this study
were obtained through approvals from the provincial and
federal governments.
Ontario’s Province-Wide Community-Based HIV
Programs
In Ontario, community-based HIV organizations are non-
profit organizations governed by independent boards,
established specifically to provide HIV prevention, edu-
cation, outreach and support services to people living with
HIV or to populations at risk of HIV (e.g., gay men, people
who inject drugs, people from countries where HIV is
endemic, and Indigenous people). It is important to include
funding for support services for people living with HIV
within prevention programming because of the critical
impact that education and support have on onward trans-
mission. Table 1 describes the major key non-biomedical
and behavioural interventions for HIV and sexually trans-
mitted infections (STIs) provided by community-based
HIV organizations in Ontario. It also cites the literature on
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Table 1 Main non-biomedical interventions for HIV and sexually transmitted infection prevention provided by community-based AIDS service
organizations and a summary of corresponding evidence of the effectiveness of these interventions
Non-biomedical intervention Target populations Examples of Ontario’s community-
based programs
Evidence of effectiveness in current
literature
Individual-, group-, and community-
level education, outreach, and
community campaigns that
promote risk-behaviour reduction
People living with HIV
Gay, bisexual and other






engage in activities with a
high risk of exposure to
HIV, or with priority
populations)
Prevention/education activities
targeted to high-risk populations
(e.g., group workshops/
presentations in varying locations
and one-on-one education through
outreach activities)
Community campaigns such as the
HIV Stigma campaign, Our
Agenda, Keep It Alive for African,
Caribbean and Black communities
etc.
Reduce odds of unprotected anal
intercourse by 27–43 %, and
increase odds of condom use by
81 % [8–9]
Promote HIV medication adherence People living with HIV Clinical counseling
Case management
Support sessions for HIV symptoms
management, treatment/
medication Adherence
Increase HIV medication adherence
behaviour and reduce HIV viral
loads among people living with
HIV [11]
Social support and social inclusion People living with HIV
People affected by HIV
(e.g. family, friends,
partners)
People at risk for HIV
Clinical counseling










A high level of social support is
associated with fewer risky sexual
behaviours [5]
Support programs can achieve a
high level of retention in care
(91.4 %) over a 4-year follow-up
[6]
Needle and syringe programs, safer
inhalation programs, harm
reduction outreach programs, and
community development for
people who use drugs
Injection drug users /
people who use drugs
Distribution of safer injection
equipment: cookers, filters,
needles, sharps containers, swabs,
ties/tourniquets, vitamin
C/acidifiers, water for injection,
and safer inhalation equipment
Harm reduction activities, outreach
and education programs (e.g. safer
injection, safer inhalation, and
safer sex practices to reduce HIV
risk and transmission)
Exposure to needle and syringe
programs was associated with
reduction of HIV transmission
(pool effect size: 0.4, 95 % CI
0.22–0.81) [2]
Community outreach programs for
injection drug users were effective
[4]
Education and support for reduction
of risky HIV transmission
behaviour
People living with HIV
Gay, bisexual and other





People who use drugs
Women at-risk (who
engage in activities with a
high risk of exposure to
HIV, or with priority
populations)
Prevention, education, and outreach
activities
Education and support programs
significantly reduced unprotected
sex (OR 0.57, 95 % CI 0.40–0.73),
and incidence of sexually
transmitted disease (OR 0.20,
95 % CI 0.05–0.73) [3]
Men living in geographic regions of
Ontario with HIV prevention
programming had unprotected
homosexual intercourse with both
casual and regular partners
significantly less frequently [60]
AIDS Behav (2016) 20:1143–1156 1145
123
Table 1 continued
Non-biomedical intervention Target populations Examples of Ontario’s community-
based programs
Evidence of effectiveness in current
literature
Mass media programs for HIV
prevention
People living with HIV
Gay, bisexual and other





People who use drugs
Women at-risk (who
engage in activities with a
high risk of exposure to
HIV, or with priority
populations)
Mass media campaigns, e.g. Keep It
Alive, HIV Stigma, Our Agenda
Increases in condom use [effect size
(d):0.25, 95 % CI 0.18–0.31],
knowledge of HIV transmission
(d: 0.30, 95 % CI 0.18–0.41),
knowledge of HIV prevention (d:
0.39, 95 % CI 0.25–0.52) [7]
Mass condom, and safer sex
materials distribution
People living with HIV
Gay, bisexual and other





People who use drugs
Women at-risk (who
engage in activities with a
high risk of exposure to
HIV, or with priority
populations)
Distribution of condoms, lubricant
and dental dams
Increased condom use (OR 1.8,
95 % CI 1.51–2.17), condom
acquisition (OR 5.4, 95 % CI
1.86–15.66), and reduced
incidence of sexually transmitted
disease (OR 0.69, 95 % CI
0.53–0.91) [10]
Practical assistance programs
(includes distribution of practical
assistance items)
People living with HIV
Gay, bisexual and other





People who use drugs
Women at-risk (who
engage in activities with a
high risk of exposure to
HIV, or with priority
populations)
People affected by HIV
Practical assistance programs, e.g.




drug payment programs, child care
subsidy, clothing, household
items, help with transportation,
assistance with tax, insurance, or
legal information
Support program can achieve a high
retention of care (91.4 %) over a
4-year follow-up [6]
Linkage to HIV care, Ontario’s
testing programs, HIV supportive
case management, and clinical
counseling
People living with HIV Case management
Support sessions that focus on
connection to HIV care, retention
in HIV care, HIV management,
supporting clients to make/keep/or
travel to medical appointments,
referrals to HIV care, testing or
treatment, or accompanying
clients to medical appointments.
Anonymous point-of-care testing as




Case management and community
engagement program increased
likelihood of retaining in care (OR
4.13, 95 % CI 1.93–8.85) [12]
Community-based approach
increased uptake of HIV testing
and counseling (RR 10.65, 95 %
CI 6.27–18.08) and increased
proportion of first-time testers (RR
1.23, 95 % CI 1.06–1.42) [55]
Support programs can achieve a
high retention of care (91.4 %)
over a 4-year follow-up [6]
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the effectiveness of each type of intervention. It is worth
noting that the services offered by Ontario’s community-
based HIV organizations differ from the HIV/STI preven-
tion services offered by the province’s public health units,
which focus mainly on providing sexual health clinics for
the general population, testing services, and tracing the
contacts of people newly diagnosed with HIV or another
STI. While both community-based HIV organizations and
public health units distribute condoms, public health con-
dom distribution programs are focused mainly on youth
with a primary goal of preventing STIs and teenage preg-
nancy, while community-based HIV organizations focus on
condom distribution to populations most at risk of HIV.
In Ontario, community-based HIV organizations are pri-
marily funded by the AIDS Bureau of the Ontario Ministry of
Health and Long-term Care (since 1987) and the AIDS
Community Action Program (ACAP) of the Public Health
Agency of Canada (since 1993). Community-based HIV
organizations also seek funding from other federal, provin-
cial, regional and local government health programs, from
foundations, and from the general public [13, 14]. In general,
about 58 % of their funding comes from the AIDS Bureau,
8 % from ACAP, 21 % from other government health pro-
grams and 13 % from other sources [13, 14].
Data Sources and Analytic Framework
Our analytic framework was based on well-established
methods used to evaluate U.S. investments in HIV preven-
tion strategies [15–21]. Analyses were conducted from the
payer perspective. Ontario HIV transmission rates were
estimated from Ontario HIV surveillance reports dating to
1986, the first full year in which HIV testing results became
available [24]. Lifetime HIV treatment costs in Canada were
obtained from the scientific literature [25]. Expenditures of
community-based HIV prevention programs were obtained
from budgetary costs submitted by all community-based
organizations [13]. All estimated costs are reported in 2011
Canadian dollars using the corresponding consumer price
indices (CPI) [26] and a discounted rate of 3 % [27, 28].
We first quantified the historical impacts of community-
based HIV programs by estimating the number of HIV cases
averted and the associated estimated cost savings to the
Ontario health care system. We then estimated the financial
return-on-investment ratio for Ontario’s investment in
community-based HIV programs from 2005 to 2011.
In our analysis, we recognize that community-based
HIV prevention programs are not the only interventions
that influence infection rates. General programs offered by
public health units contribute as do biomedical treatment
programs (i.e., the use of antiretroviral therapy, which
reduces infectiousness).
To estimate the number of HIV infection cases averted
by province-wide community-based HIV programs, we first
used the differential in HIV transmission rates between
Ontario and a comparator (which was assumed to not have
Ontario’s HIV prevention programs) to estimate the total
number of HIV infections averted by both biomedical (i.e.,
antiretroviral therapy-related) and non-biomedical (i.e.
community-based and public health) interventions in
Ontario. The HIV transmission rate of the comparator was
assumed to be the mean of Ontario’s incidence rates from
1987 (when community-based and public health programs
began) to 1996 (1 year before highly active antiretroviral
therapy [HAART] became available). The comparator was
Ontario itself—only assuming a period with no HIV
Table 1 continued
Non-biomedical intervention Target populations Examples of Ontario’s community-
based programs
Evidence of effectiveness in current
literature
Increase awareness of use of post-
exposure prophylaxis (PEP)
People living with HIV
Gay/bi/trans and other men
who have sex with men
Education activities include group
workshops/presentations and one-
on-one education through outreach
targeted to priority populations
Support sessions provided to clients
at Ontario’s community-based
HIV organizations
Increased use of PEP for HIV by
42 % [62]
Supportive housing People living with HIV HIV supportive housing programs
across Ontario: Fife House &
McEwan Housing and Support
Services (Toronto), AIDS Niagara
(St. Catherines), Bruce House
(Ottawa), John Gordon Home-
Regional HIV/AIDS Connection
(London), and Abercrombie Place-
ARCH (Guelph)
Homeless/ marginally-housed
people living with HIV were
associated with poorer HAART
access/adherence or treatment
outcomes [63]
Housing status reduces needle
sharing (OR 0.37, 95 % CI
0.15–0.81) and unprotected sex
(OR 0.39, 95 % CI 0.18–0.84)
[64]
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prevention programs or very minimal programming—so
that systematic differences between Ontario and the com-
parator were minimized. Our assumption of the compara-
tor’s HIV transmission rate was conservative because we
used average rates from a period when public health and
community-based programs were already in place.
Once we had the total number of HIV cases averted by
Ontario’s HIV prevention programs, we factored in the
number of cases averted by type of intervention based on
literature-based proportions during both the pre-HAART
and post-HAART eras. During the pre-HAART era (before
1997), we assumed that all the HIV infection cases averted
were due to province-wide community-based and public
health programs. We also assumed (conservatively) that
30 % of the HIV cases averted were due to the effort of
Ontario’s STI public health control programs, although a
recent mathematical model has found that the probability
of HIV infections averted due to STI preventions (cofactors
and STI screening) was about 15 % [23, 29].
During the post-HAART era (1997 and onwards), we
assumed that biomedical interventions were responsible for
averting 75 % of new infections while non-biomedical
programs (public health and community-based programs)
helped to avert 25 % of new diagnoses. Our assumptions are
very conservative because the effect of the introduction of
antiretroviral therapy on HIV prevention in developed
countries was estimated at 25 % [23, 30] and the theoretical
efficacy (universal annual screening, immediate linkage to
care, universal ART and perfect adherence) of implementing
HAART-related interventions is unlikely to be achieved in
real world settings. In addition, a recent mathematical model
demonstrated a few counter-factual scenarios in a simple
world for HIV epidemics based on having only ART and
condoms (the key representation of non-ART intervention)
for HIV prevention. If no ART were introduced and all
condom use ceased, the mean HIV incidence would have
increased by 0.36 and 2.25 respectively [30]. These scenarios
give a rough idea that approximately 14 and 86 % of the total
decrease of HIV incidence was attributed to ART introduc-
tion and to condom use respectively [30]. For the total
number of cases averted by non-biomedical interventions,
we assumed that about 30 % were averted by the efforts of
public health programs for STI prevention.
We estimated savings in Canadian health care system costs
by multiplying the number of HIV infection cases averted
(attributed to community-based HIV programs) by the lifetime
treatment cost associated with HIV infection. Annual direct
costs for treating HIV were estimated by conducting a litera-
ture review for cost-of-illness studies published between Jan-
uary 1, 1986 and December 31, 2012 using HealthSTAR,
Medline, PubMed, EMBASE, Cochrane databases and grey
literature (i.e., government or non-government reports, theses,
dissertations, and conference proceedings). Search terms
included: ‘‘cost of illness,’’ ‘‘costs,’’ ‘‘health expenditures,’’
‘‘cost analysis,’’ ‘‘economic value of life,’’ ‘‘direct cost,’’ and
‘‘medical cost.’’ We included studies: (a) with HAART as a
routine clinical treatment; (b) from the Canadian health care
system; and (c) concerning people living with HIV in general.
Seven academic articles [31–35] and grey literature reports
[36, 37] were found. Four articles [31, 32, 34, 35] were not
related to estimating direct medical costs and the methods in
two reports [36, 37] were not rigorous. Our estimate for the
direct costs to treat HIV was based on a retrospective cohort
study conducted in Alberta, Canada by Krentz et al. [33]. The
mean treatment cost per patient per month (PPM) was esti-
mated as $1,159 (in 2005 Canadian dollars), varying from
$979 to $2,687 PPM depending on the stage of HIV infection
[33]. Therefore, using the corresponding CPIs, the mean
treatment cost per patient per year was estimated as $13,908 (in
2005 Canadian dollars) (calculated as $1,159 9 12 months).
Considering the type of drug therapy and CD4 counts when
first infected, the number of years on ART was assumed to be
between 19 and 32 years from the time of infection [1, 38, 39].
Using a discount rate of 3 % [27, 28], the present value of the
mean lifetime treatment cost for HIV infection in Canada was
approximately $256,090 per patient in 2005 Canadian dollars,
varying from $213,123 to $297,475. Using the corresponding
CPIs [26], the present value of the mean lifetime treatment cost
for HIV infection is $286,965 in 2011 Canadian dollars,
varying from $238,817 to $333,339.
We estimated the financial return-on-investment (ROI)
ratio [40, 41] for Ontario’s investments in community-
based HIV programs (from 2005 to 2011) by dividing the
net present value of net savings in health care costs from
averted HIV cases by the total investments in community-
based HIV programs, in 2011 dollars, discounted at 3 %.
Completed budgetary data for community-based HIV
programs were not available prior to 2005.
Sensitivity Analyses
Several one-way sensitivity analyses were conducted to
examine the impact of assumptions made in analyzing the
number of HIV infections averted and the savings attrib-
uted to community-based HIV programs in the health care
system. First, we assessed the impact by assuming that the
HIV transmission rate of the comparator was the largest or
the smallest transmission rate from 1987 to 1996 (the pre-
HAART era) in Ontario. Second, we reduced our assumed
proportion of averted HIV infections that were attributed to
public health STI programs from 30 % to a more realistic
proportion of 15 % [23, 29]. Third, we reduced our
assumed proportion of the averted HIV infections that were
attributed to the introduction of antiretroviral therapy from
75 % to a more realistic proportion of 25 % [23, 30].
Fourth, we assessed the impact by assuming the discount
1148 AIDS Behav (2016) 20:1143–1156
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rate of 5 % for deriving the present value of lifetime HIV
treatment costs. Finally, we simultaneously varied two or
more of our assumptions to examine the impact on our
results.
Results
Table 2 presents the estimated number of new HIV cases
averted by all types of HIV prevention strategies in Ontario
from 1987 to 2011. Overall, during this period and in
contrast to the comparator (without HIV prevention
strategies in place), we estimated that approximately
70,279 new HIV infection cases were averted by Ontario’s
HIV prevention strategies. When stratified by intervention
type, we estimated that about 46,462, 7145 and 16,672 new
HIV cases were averted by biomedical, public health, and
community-based HIV programs respectively during this
period (Fig. 1).
In terms of the corresponding economic impacts, we
estimated that a total of $25.3 billion CAD (range
$18.8–29.4 billion) (in 2011 dollars, 1 USD = 0.99 CAD
[42]) was saved in the Ontario health care system (see
Fig. 1) from 1987 to 2011. Based on type of intervention,
Table 2 HIV incidence, prevalence, and transmission rate and total number of HIV infections averted (in cases) in Ontario (1987–2011)
Year Ontario Comparatora New HIV infection cases Total HIV
infection averted














(A) = [(4) 9 (2)] 7 100
Ontario
(B) = [(3) 9 (2)] 7 100
1987 1546 1546 53.1 20.8 321.6 821.3 0.0
1988 1442 4352 33.1 20.8 905.3 1442.0 0.0
1989 1702 6054 28.1 20.8 1259.4 1702.0 0.0
1990 2062 8116 25.4 20.8 1688.3 2062.0 0.0
1991 1822 9938 18.3 20.8 2067.3 1822.0 245.3
1992 1797 11735 15.3 20.8 2441.1 1797.0 644.1
1993 1477 13212 11.2 20.8 2748.4 1477.0 1271.4
1994 1304 14516 9.0 20.8 3019.7 1304.0 1715.7
1995 1314 15830 8.3 20.8 3293.0 1314.0 1979.0
1996 1034 16864 6.1 20.8 3508.1 1034.0 2474.1
1997 924 17788 5.2 20.8 3700.3 924.0 2776.3
1998 953 18741 5.1 20.8 3898.6 953.0 2945.6
1999 889 19630 4.5 20.8 4083.5 889.0 3194.5
2000 886 20,516 4.5 20.8 4267.8 923.2 3344.6
2001 957 21,473 4.6 20.8 4466.9 987.8 3479.1
2002 1,132 22,605 5.2 20.8 4702.4 1175.5 3526.9
2003 1,164 23,769 4.8 20.8 4944.5 1140.9 3803.6
2004 1,085 24,854 4.9 20.8 5170.2 1217.8 3952.4
2005 1,106 25,960 4.4 20.8 5400.3 1142.2 4258.0
2006 1,132 27,092 4.3 20.8 5635.8 1165.0 4470.8
2007 1,049 28,141 3.9 20.8 5854.0 1097.5 4756.5
2008 1,102 29,243 3.9 20.8 6083.2 1140.5 4942.7
2009 999 30,242 3.4 20.8 6291.0 1028.2 5262.8
2010 1,023 31,265 3.3 20.8 6503.8 1023.0 5480.8
2011 946 32,211 2.9 20.8 6700.6 946.0 5754.6
Total 99,055.1 30,628.9 70,278.9
a HIV transmission rate of the comparator was assumed to be the mean of Ontario’s incidence rates from 1987 to 1996 [i.e., a time when the
investments of community-based and public health programs had begun (1987) and before the introduction of highly active antiretroviral therapy
(HAART) (1996)]. Our comparator was Ontario itself, so systematic differences between Ontario and the comparator were minimized. Our
assumption of the comparator’s HIV transmission rate was conservative because we used average rates during a period when public health and
community-based programs were already in place
b Per 100 persons living with HIV
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about $16.1 billion CAD (range $11.9–18.7 billion), $2.8
billion CAD (range $2.1–3.2 billion), and $6.5 billion CAD
(range $4.8–7.5 billion) were saved by biomedical, public
health, and community-based HIV strategies respectively
(see Fig. 1).
Table 3 presents the results of the financial ROI ratio for
community-based HIV programs in Ontario from 2005 to
2011. Completed budgetary data for community-based
HIV programs were not available prior to 2005. During the
period from 2005 to 2011, approximately $328 million (in
2011 dollars, discounted by 3 %) were invested in com-
munity-based HIV programs and these programs helped to
save about $1.9 billion (in 2011 dollars, discounted by
3 %). Thus, the financial ROI ratio was about 4.8 (i.e., a
dollar invested in community-based HIV programs would
save the Ontario health care system approximately $5
dollars in treatment costs).
Figure 2 presents the results of a series of sensitivity
analyses for the impacts on health care savings attributed to
community-based HIV programs. The results were sensi-
tive to our assumptions. By assuming that the HIV trans-
mission rate of the comparator was the largest HIV
transmission rate in Ontario during the pre-HAART era,
the health care savings increased by approximately 278 %
Fig. 1 Estimated number of HIV infections averteda and savings to
the Canadian health care system (in millions)b by intervention type in
Ontario (1987–2011). Notes (a) number of HIV infection cases
averted by province-wide community-based HIV prevention pro-
grams was estimated in two steps. We first used the differential in
HIV transmission rates between Ontario and a comparator to estimate
the total number of HIV infections averted by both biomedical (i.e.
antiretroviral therapy-related) and non-biomedical (i.e. community-
based and public health program) interventions in Ontario. The HIV
transmission rate of the comparator was assumed to be the mean of
Ontario’s incidence rates from 1987 to 1996 (when investments in
community-based and public health programs had begun but HAART
was not yet in place). Once we had the total number of HIV cases
averted by the Ontario’s HIV prevention programs, we factored in the
number of cases averted by type of intervention based on literature-
based proportions. We assumed conservatively that 30 % of the HIV
cases averted were due to the effort of Ontario’s STI public health
control programs (although results of a recent mathematical model
suggest that the probability of HIV infections averted due to STI
preventions [cofactors and STI screening] was about 15 %) [23, 29].
During the post-HAART era (1997 and onwards), we assumed the
proportion of HIV infection cases averted by biomedical programs as
75 % of the total number of the cases averted and by non-biomedical
programs (public health and community-based programs) as 25 % of
the total cases averted [23, 30]. Our comparator was Ontario itself, so
systematic differences between Ontario and the comparator were
minimized. Our assumption of the comparator’s HIV transmission
rate was conservative because we used average rates during a period
when public health and community-based programs were already in
place. (b) Savings in Canadian healthcare system costs were estimated
by multiplying the number of HIV infection cases averted (attributed
to community-based HIV programs) by the lifetime treatment cost
associated with HIV infection. Mean lifetime medical costs were
estimated as $286,965 (range $238,817–$333,339) per patient in 2011
Canadian dollars. All estimated savings are reported in 2011 CAD
using the corresponding consumer price indices in Ontario [26].
(c) Biomedical interventions were assumed to be related to the
introduction of antiretroviral therapy. (d) Public health programs were
assumed to be mainly focused on sexually transmitted infections
(STIs). These programs included a wide range of initiatives, e.g.
medications to treat STIs, education and outreach programs, needle
exchange programs, sexual health hotlines, etc. (e) Community-based
programs were assumed to be non-biomedical interventions excluding
public health sexually transmitted infection control programs [26]
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(see case #1). Second, assuming that the HIV transmission
rate of the comparator was the smallest HIV transmission
rate in Ontario during the pre-HAART era, the savings
were reduced by approximately 95 % (see case #2). Third,
by assuming a more realistic proportion (15 %) of averted
HIV infections attributed to public health STI programs,
the savings increased by 21 % (see case # 3). Fourth, by
assuming the effect of the introduction of the antiretroviral
therapy on HIV prevention at a more realistic proportion of
25 %, the savings were increased by approximately 151 %
(see case #4). Fifth, when assuming the discount rate of
5 % for deriving the present value of the lifetime treatment
cost for HIV, the savings increased by 386 % (see case #5).
Finally, by changing two to three assumptions simultane-
ously, the changes in savings attributed to community-
based HIV programs varied from -95 % to ?774 % (see
cases #6–22).
Discussion
Our macro-level analysis is the first study to attempt to
quantify the historical and economic impacts of province-
wide, community-based programs for HIV prevention in
Ontario. From 1987 to 2011, our results show that these
programs might have helped to avert approximately 16,672
new cases of HIV infection, and saved a total of $6.5 bil-
lion (range 4.8–7.5B) for the Ontario health care system (in
2011 Canadian dollars). We also showed that community-
based HIV programs were cost-saving because every $1
invested in these programs from 2005 to 2011 saved about
$5 in treatment costs. Nonetheless our evaluation was
conducted at macro-level. It did not attempt to assess
which types of community-based prevention interventions
were most effective.
Our results are consistent with similar studies in other
jurisdictions. Our projection of the number of HIV infec-
tions that would occur if HIV prevention interventions
were not in place is comparable to the U.S. CDC estimates
[17–21]. In Ontario, the HIV prevention strategy has relied
heavily on community actions and programs since the
beginning of the epidemic [43]. Similarly, Australian
researchers have found that community-based HIV pre-
vention programs/actions have had a remarkable impact on
reducing HIV incidence [44]. Community-based HIV pre-
vention in Australia has been credited as a ‘‘public health
milestone of global importance’’ in reducing HIV cases in
the past two decades [44]. This type of data on the cost
saving potential of investments in community-based pro-
grams may be particularly helpful to the Ontario health
care system, which—unlike the mixed private–public
funded system in the U.S.—is predominantly a single
Table 3 Financial return on investment from Ontario’s investment in community-based programs for HIV infections (2005–2011)
Year Savings in Canadian
health care system by
community-based
programsa
Investments in community-based HIV programs
AIDS Bureaub ACAPc Other
governmentald
Otherse
2005 $ 213,833,757 $ 12,644,074 $ 2,534,540 $ 8,118,491 $ 10,222,525
2006 $ 224,518,625 $ 13,607,252 $ 3,323,877 $ 9,532,182 $ 10,037,582
2007 $ 238,864,805 $ 13,830,988 $ 2,441,225 $ 9,948,038 $ 9,904,051
2008 $ 248,218,737 $ 16,567,895 $ 3,252,240 $ 11,584,297 $ 10,968,874
2009 $ 264,291,987 $ 17,698,104 $ 3,796,024 $ 12,058,316 $ 7,962,258
2010 $ 275,241,483 $ 20,083,701 $ 3,564,936 $ 14,223,361 $ 10,125,239
2011 $ 288,990,894 $ 20,338,042 $ 3,859,085 $ 13,106,427 $ 9,719,275
Total $ 1,753,960,288 $ 114,770,056 $ 22,771,927 $ 78,571,112 $ 68,939,804
Present value of total savings in Canadian health care system (2005–2011) (in 2011 dollars, discounted by 3 %)f (A) $ 1,908,564,059
Present value of investments in community-based HIV programs (2005–2011) (in 2011 dollars, discounted by 3 %)f (B) $ 327,793,439
Financial return on investment ratio (C) = [(A) - (B)]/(B) 4.8
a Savings in Canadian health care system costs were estimated by multiplying the number of HIV infection cases averted (attributed to
community-based HIV programs) by the lifetime treatment cost associated with HIV infection. Mean lifetime medical costs were estimated as
$286,965 (range $238,817–$333,339) per patient in 2011 Canadian dollars. All estimated savings are reported in 2011 CAD using the corre-
sponding consumer price indices in Ontario [26]
b AIDS Bureau of the Ontario Ministry of Health and Long-term Care (MOHLTC)
c AIDS Community Action Program (ACAP) managed by the Public Health Agency of Canada Regional Offices
d Other governmental funding includes other federal, provincial, regional, and municipal-level funding sources
e Other sources includes charitable donations, fundraising, United Way, and others
f Reported present value in 2011 dollars using the corresponding consumer price indices [26] and a discount rate of 3 %
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(government) payer system. Savings from investments in
prevention programs accrue back to system, where they can
be reallocated to other health priorities.
Our results for the financial ROI ratio for community-
based HIV programs were comparable to findings of ROI
ratios in mental health promotion programs and other
public health strategies, which ranged from $1 to $25 [45–
47]. Our ROI estimate was conservative because we only
included savings in direct health care costs as opposed to
the broader health and social benefits of averted HIV
infections.
Over the past 28 years, Ontario’s community-based HIV
programs have made significant efforts to reach popula-
tions and communities at risk, and to develop the kind of
meaningful relationships and programs that lead to good
health outcomes, including a reduction in new infections
[13, 14]. Even in the post-antiretroviral therapy era, with
its strong focus on treatment-related prevention, more and
more evidence is showing that biomedical and social
behavioral interventions are essential complements to each
other in order to deliver effective combination prevention
programs [9, 23, 30, 48–51]. Social behavioural and
structural interventions, together with community actions,
are important at each step to help people living with HIV
achieve virologic suppression, including interventions that
respond to stigma, engage patients in HIV testing, initiate
ARV medication, maintain long-term adherence to ARV,
and retain patients in HIV care [49–53]. Given the com-
prehensive nature of community-based HIV prevention
programs in Ontario and the emerging evidence on the
effectiveness of combination approaches to prevention, our
findings are likely a conservative estimate of the impact of
Ontario’s investment in community-based programs for
HIV prevention.
Our study has several limitations. First, the economic
evaluation analyses relied on aggregate-level data and the
ecological analysis might not have allowed our analysis to
consider heterogeneity among individuals or to control for
other confounding factors over time. However, these types
of methods and analytic approaches have been previously
used in many U.S. studies to successfully evaluate their
HIV prevention programs and strategies [15–21].
Second, we made the causal assumption in our analysis
that community-based HIV prevention programs in Ontario
can reduce new HIV infections. However, this is a rea-
sonable assumption given that many of the community-
based HIV prevention programs in Ontario are evidence-
based, and the effectiveness of these types of programs
have been shown in the literature as summarized in Table 1
[2, 4, 5, 7, 8, 54–60]. In addition, an outcomes evaluation
report, based on sound qualitative methods, found that
Ontario’s community-based HIV programs are effective in
reaching vulnerable and marginalized populations,
increasing awareness and knowledge of HIV transmission
and consequences, reducing risky behaviour for HIV
infection, and increasing linkage to HIV care, support and
treatment [14]. The report also concluded that successful
HIV prevention outcomes are likely to be achieved by
effective collaboration among healthcare providers, social
services and community-based programs [14]. Future
research should assess the effectiveness and cost-effec-
tiveness of specific prevention programs at the individual
level in community-based settings.
Third, we compared the yearly HIV transmission rate to
the mean of Ontario’s incidence rates from 1987 to 1996 in
order to estimate the total number of HIV infections
averted by both biomedical (i.e. antiretroviral therapy-re-
lated) and non-biomedical (i.e. community-based and
public health program) interventions in Ontario. Our
comparator is a reasonable and conservative choice. During
this period, investments in community-based and public
health programs had begun and HAART was not yet in
place. As well, our comparator was Ontario itself, so sys-
tematic differences between Ontario and the comparator
were minimized.
Fourth, our results were shown to be sensitive to our
assumptions. By changing one or more assumptions, the
changes in saving attributed to community-based HIV
programs varied from -95 to ?774 % (see Fig. 2). Nev-
ertheless, all negative changes in our savings estimate were
due to the fact that we varied the HIV transmission rate of
the comparator to the lowest HIV transmission rate in
Ontario during the pre-HAART era (see Table 2).
bFig. 2 Sensitivity analysesa for examining impacts on savingsb in
Canadian health care systems attributed to community-based pro-
gramsc for HIV Prevention through varying one or more assumptions.
Notes (a) Varies one or more assumptions simultaneously. (b) Medical
system savings are calculated based on the estimated mean of lifetime
medical costs, or $286,965 (range $238,817–$333,339) per patient in
2011 Canadian dollars. All estimated savings are reported in 2011
CAD using the corresponding consumer price indices in Ontario [26].
(c) Community-based programs were assumed to be non-biomedical
interventions excluding public health sexually transmitted infection
control programs. Non-biomedical interventions were assumed to be
mainly education, outreach, and social behavioural programs that
were not related to the introduction of antiretroviral therapy (e.g.
condom distribution programs, community outreach, needle exchange
programs, sexual education, programs for improving antiretroviral
adherence or increasing awareness of the use of post-exposure
prophylaxis, etc.). HIV transmission rate of the comparator was the
largest transmission (53.1 per 100 persons living with HIV) rate from
1987 to 1996 (pre-HAART era) in Ontario. (d) HIV transmission rate
of the comparator was the smallest transmission (6.1 per 100 persons
living with HIV) rate from 1987 to 1996 (pre-HAART era) in Ontario.
(e) A more realistic proportion (15 %) of averted HIV infections were
assumed to be attributable to public health STI programs [23, 29].
(f) We assumed the effect of the introduction of antiretroviral therapy
on HIV prevention at a realistic proportion of 25 % [23, 30]. (g) We
assumed the discount rate of 5 % for deriving the present value of
lifetime HIV treatment costs
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However, the lowest HIV transmission rate occurred in
1995 (see Table 2), when most of public health and com-
munity-based HIV programs were well-established. In
addition, our assumption of the comparator’s HIV trans-
mission rate was conservative because we used average
rates from a period when public health and community-
based HIV programs were already in place. Furthermore, as
already discussed, we assumed the proportion of HIV
infection cases averted by biomedical programs at the
theoretical efficacy rate of 75 %, which is high given that
the estimated effect of the introduction of antiretroviral
therapy in the real world is 25 % [23, 30]. Moreover, we
assumed that 30 % of the HIV cases averted were due to
the effort of Ontario’s STI public health control programs,
even though the results of a recent mathematical model
suggest a rate of about 15 % [23, 29].
Despite these limitations, our results shed some light on
investments made in community-based HIV prevention
programs in Ontario and how these investments have
reduced HIV infections and health care system costs. Given
that an effective vaccine for HIV is not yet available [61]
and that the HIV epidemic is far from over [24, 25], con-
tinued investments in a combination of effective and evi-
dence-based programs is essential, particularly in the post-
HAART era. A more holistic approach that strategically
and effectively combines evidence-based community
actions, public health, biomedical, structural, and socio-
behavioural efforts will likely yield the most significant
impact on reducing new HIV infections [49–53].
Future research should provide individual-level eco-
nomic evidence of the impact of investments in commu-
nity-based HIV prevention programs to help both
provincial and federal governments make strategic deci-
sions about how to have the most impact on the HIV epi-
demic in Ontario, especially in an environment of
constrained health care resources.
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